Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CaSR agonist

A technology of substituent and carbon number, applied in the field of CaSR agonists

Active Publication Date: 2014-08-13
EA PHARMA CO LTD
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature documenting its relationship with "calcium-sensing receptor (CaSR) or G protein-conjugated receptor", "a strong taste", "diarrhea (syndrome) or hyperparathyroidism", which are the characteristics of the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CaSR agonist
  • CaSR agonist
  • CaSR agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0205] Examples are given below to illustrate the present invention in more detail, but these examples do not limit the present invention.

[0206] In the present specification, the conventional method refers to a method generally used as a chemical operation represented by liquid separation operation, drying, filtration, and concentration.

[0207] In this specification, the purification step A means that the crude product obtained by a conventional method is supplied to reversed-phase high performance liquid chromatography using octadecyl chemically bonded silica gel (ODS) as a filler, and is purified with 0.1% trifluoroacetic acid ( The mixed solution of water and acetonitrile of v / v) is eluted, the method for concentrating, freeze-drying target component.

[0208] Hereinafter, the synthesis of typical compounds of the present invention shown in Table 1 will be described in more detail by citing examples, but the compounds of the present invention are not limited to these e...

Synthetic example 1

[0214] (Synthesis Example 1)N 5 Synthesis of -(3-sulfophenyl)-L-glutamine (Compound No.1)

[0215] 75mg (0.247mmol) Boc-Glu-OtBu, 112mg (0.296mmol) HATU, 41mg (0.296mmol) HOAt were dissolved in 1ml DMF, 52μl triethylamine was added, and stirred at room temperature for 10 minutes. 43 mg (0.247 mmol) of 3-sulfoaniline was added thereto, followed by stirring at room temperature overnight. After distilling off the solvent, the obtained intermediate was purified by purification step A, dissolved in 2 ml of trifluoroacetic acid, stirred at room temperature for 3 hours, and then the solvent was distilled off. The product was purified by Purification Step A to afford the title compound.

[0216] Yield: 30.8 mg (0.10 mmol), yield: 41%.

[0217] 1H-NMR (D2O, 300MHz): δ7.89(s, 1H), 7.67-7.62(m, 2H), 7.58-7.53(m, 1H), 3.99(t, 1H, J=6.4Hz), 2.73- 2.66(m, 2H), 2.33-2.25(m, 2H)

[0218] ESI(m / z): 303[M+H]+, 301[M-H]-

Synthetic example 2

[0219] (Synthesis Example 2)N 5 Synthesis of -(4-methoxy-3-sulfophenyl)-L-glutamine (Compound No.2)

[0220] Using p-anisidine-3-sulfonic acid instead of 3-sulfoaniline in Synthesis Example 1, the same operation was carried out to obtain the title compound.

[0221] Yield: 24.7 mg, yield: 23%.

[0222] 1H-NMR (D2O, 300MHz): δ7.96(s, 1H), 7.53(d, 1H), 7.04(d, 1H), 3.98(t, 1H), 3.78(s, 3H), 2.63-2.52( m, 2H), 2.30-2.05 (m, 2H)

[0223] ESI(m / z): 333[M+H]+

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

Description

[0001] This application is a divisional application of the Chinese patent application with the application number 200980148983.0, the application date is October 5, 2009, and the invention name is "CaSR agonist". technical field [0002] The present invention relates to a glutamic acid derivative having CaSR agonistic activity or a pharmaceutically acceptable salt thereof, and a CaSR agonist containing the derivative or a pharmaceutically acceptable salt thereof as an active ingredient, a pharmaceutical composition, and a diarrhea medicine A prophylactic or therapeutic drug and a kokumi (コク味) administering agent. Background technique [0003] Calcium Sensing Receptor (Calcium Sensing Receptor: CaSR) is also called calcium receptor, and the receptor signal regulates various functions in organisms. There is a possibility that substances having CaSR agonistic activity can be used for the treatment or prevention of various diseases, and Possibility of use as a kokumi imparting a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07F9/38C07F9/40C07C309/51C07C237/04A61K31/662A61K31/255A61K31/198A61P1/12A23L1/228A23L1/305A23L27/00A23L27/20A23L27/22
CPCC07F9/4018A23L1/3051A23L1/228C07C309/51C07F9/3834C07F9/4021C07C237/04A23L1/22657A23L27/22A23L33/175A23L27/204A61P1/10A61P1/12A61P43/00
Inventor 杉木正之冈松亨S.朝里河户弥生畑中敏宏矢野彻雄关幸惠宫村直宏长崎浩明江藤让安田礼子
Owner EA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com